Comparative Characteristics of Inactivation Agents for HFRS Vaccine Development
https://doi.org/10.31631/2073-3046-2018-17-4-26-29
Abstract
The results of various methods of Puumala virus inactivation, including ultraviolet rays (UV), β -propiolactone (BPL) and formalin are presented. Immunogenicity of vaccine preparations obtained using these virus inactivation methods did not differ significantly in the experiments on BALB/c mice. Essential advantage of UV and BPL in relation to formaldehyde is the short time of virus inactivation.
About the Authors
C. C. Kurashova
Federal State Budget Institution of Science «Chumakov Federal Scientific Center for Research and Development of Immune-andBiological Products of Russian Academy of Sciences»
Russian Federation
Russian Federation
A. A. Ishmukhametov
Federal State Budget Institution of Science «Chumakov Federal Scientific Center for Research and Development of Immune-andBiological Products of Russian Academy of Sciences»$
Sechenov First Moscow State Medical University, of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Aidar I. Ishmukhametov – Dr. Sci. (Med.), Professor, General Director of «Federal Research Center for Research and Development of Immunobiological Preparations named after M. P. Chumakov Institute»
Moscow
M. C. Egorova
Federal State Budget Institution of Science «Chumakov Federal Scientific Center for Research and Development of Immune-andBiological Products of Russian Academy of Sciences»
Russian Federation
Moscow
Russian Federation
Moscow
M. V. Balovneva
Federal State Budget Institution of Science «Chumakov Federal Scientific Center for Research and Development of Immune-andBiological Products of Russian Academy of Sciences»
Russian Federation
Moscow
Russian Federation
Moscow
T. K. Dzagurova
Federal State Budget Institution of Science «Chumakov Federal Scientific Center for Research and Development of Immune-andBiological Products of Russian Academy of Sciences»
Russian Federation
Moscow
Russian Federation
Moscow
E. A. Tkachenko
Federal State Budget Institution of Science «Chumakov Federal Scientific Center for Research and Development of Immune-andBiological Products of Russian Academy of Sciences»$
Sechenov First Moscow State Medical University, of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Evgeny A. Tkachenko – Dr. Sci. (Med.), professor, leader of of «Federal Research Center for Research and Development of Immunobiological Preparations named after M. P. Chumakov Institute»
Moscow
References
1. Tkachenko E. A., Dzagurova Т.К., Ishmukhametov А.А. Hemorrhagic fever with renal syndrome in Russia: successes and actual problems at the present stage. Biomedicine of the XXI century: achievements and perspective directions of development. Collection of scientific papers. 2016; 331–344 (in Russian).
2. Martin, S. S., Bakken, R. R., Lind, C. M., Garcia, P., Jenkins, E., Glass, P. J., Fine, D. L. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. Vaccine. 2010; 28 (4): 1031–1040.
3. Alsharifi M., Mullbacher A. The γ-irradiated influenza vaccine and the prospect of producing safe vaccines in general //Immunology and cell biology. 2010; 88 (2): 103–105.
4. Budowsky, E. I., Kostyuk, G. V., Kost, A. A., Savin, F. A. Principles of selective inactivation of viral genome. Archives of virology. 198; 68 (3): 239–247.
5. Nims R. W., Plavsic M. Polyomavirus inactivation – a review. Biologicals. 2013; 41 (2): 63–70.
6. Sanders B., Koldijk M., Schuitemaker H. Inactivated viral vaccines //Vaccine Analysis: Strategies, Principles, and Control. Berlin, Heidelberg; Springer, 2015; 45–80.
7. Tkachenko E. A., Ishmukhametov А. А., Dzagurova Т. К., Sinugina А. А., Korotina N. А., Nabatnikov P. А. et al. Manufacturing techniques and methods of control inactivated Vero cells-derived vaccine against HFRS developed in Russia. Remedium. 2015; 6: 47–53 (in Russian).
8. Barkhaleva О. А., Vorobyeva М. S., Ladizhenskaya I. P., Tkachenko E. A., Dzagurova Т. К. Vaccine against hemorrhagic fever with kidney syndrome. Biopreparations. 2011; 1: 27–30 (in Russian).
9. Colburn N. H., Richardson R. G., Boutwell R. K. Studies of the reaction of β-propiolactone with deoxyguanosine and related compounds. Biochemical pharmacology. 1965; 14 (7): 1113–1118.
10. Mate U., Solomon J. J., Segal A. In vitro binding of β-propiolactone to calf thymus DNA and mouse liver DNA to form 1-(2-carboxyethyl) adenine. Chemico-biological interactions. 1977; 18 (3): 327–336.
11. Roberts J. J., Warwick G. P. The reaction of β-propiolactone with guanosine, deoxyguanylic acid and RNA. Biochemical pharmacology. 1963; 12 (12): 1441–1442.
12. Hartman F. W., LoGrippo G. A. Beta-propiolactone in sterilization of vaccines, tissue grafts, and plasma //Journal of the American Medical Association. 1957; 164 (3): 258–260.
13. Lawrence S. A. β-Propiolactone: viral inactivation in vaccines and plasma products. PDA journal of pharmaceutical science and technology. 2000; 54 (3): 209–214.
Review
For citations:
Kurashova C.C., Ishmukhametov A.A., Egorova M.C., Balovneva M.V., Dzagurova T.K., Tkachenko E.A. Comparative Characteristics of Inactivation Agents for HFRS Vaccine Development. Epidemiology and Vaccinal Prevention. 2018;17(4):26-29. (In Russ.) https://doi.org/10.31631/2073-3046-2018-17-4-26-29
Views:
934
Email this article 